Cure My Disease

Don't miss your cure!

 Log in / Sign up

A web program may ease the emotional toll of chemotherapy hair loss

NCT ID NCT07724314

Symptom relief Sponsor: Gulay Akman Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This trial tests whether a web-based education program can improve body image, self-esteem, and quality of life in women with breast cancer who lose their hair during chemotherapy. The program provides information on hair loss, scalp care, wigs, and emotional coping strategies. Researchers will compare outcomes between women who receive the program and those who get standard care alone.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a structured web-based educational and supportive care program covering hair loss preparation, scalp care, wig use, and coping strategies
What this could lead to
If effective, this program could offer a low-cost, accessible way to improve body image and quality of life for women facing chemotherapy-induced hair loss.
What could go wrong
This is a small, single-site trial with 68 participants, so results may not apply broadly. The program's benefits depend on participants' engagement and may not outperform routine care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

68 people

The number who actually took part.

Started

Jul 2018

Finished

May 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female participants aged 18 to 65 years. * Diagnosed with stage I or stage II breast cancer. * Receiving chemotherapy for the first time. * Scheduled to receive one of the following 21-day chemotherapy regimens: doxorubicin plus cyclophosphamide (AC); epirubicin plus cyclophosphamide (EC); docetaxel plus cyclophosphamide (TC); cyclophosphamide, doxorubicin, and fluorouracil (CAF); cyclophosphamide, epirubicin, and fluorouracil (CEF); or docetaxel, doxorubicin, and cyclophosphamide (TAC). * Scheduled to receive a chemotherapy regimen expected to cause grade 2 alopecia according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03 (NCI-CTCAE v4.03). * Eastern Cooperative Oncology Group (ECOG), World Health Organization (WHO), or Zubrod performance status of 0 to 2. * Able to read, write, and communicate in Turkish. * Had access to a computer or internet-enabled mobile phone. * Willing to participate in the study and provide informed consent. Exclusion Criteria: * Diagnosed with stage III or stage IV breast cancer. * History of another malignancy. * History of alopecia before the current chemotherapy treatment. * Previous mastectomy. * History of a disease or condition that caused a visible alteration in physical appearance. * Diagnosed psychiatric disorder.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm chemotherapy-induced alopecia Psychological Well-Being

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Chemotherapy-induced alopecia

Contacts and locations

Locations

  • Samsun Training and Research Hospital

    Samsun, Samsun, 55105, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.